Results 1 to 10 of about 2,579 (176)

Case Report: Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder: Diagnostic Challenges and Transition From B‐Cell Depletion Therapy to Ravulizumab [PDF]

Clin Case Rep
ABSTRACT This case report illustrates the real‐world efficacy of complement component 5 inhibitors in a patient with neuromyelitis optica spectrum disorder who switched from rituximab because of B‐cell repopulation occurring early in the course of treatment.
Zabeti A.
europepmc   +2 more sources

Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". [PDF]

Ann Clin Transl Neurol
Gerischer L, Schroeder-Braunstein J, Wabnitz G, Meisel A.   +3 more
europepmc   +1 more source

FcRn antagonist and C5 complement inhibitor as early rescue strategies in severe Myasthenia Gravis: a two-case report. [PDF]

Front Immunol
Parisi M, Molitierno N, Alberti C, Gagliardi D, Velardo D, Comi GP, Corti SP.   +6 more
europepmc   +1 more source

Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series. [PDF]

Neurol Ther
Zanghì A, Di Filippo PS, Rutigliano C, Avolio C, D'Amico E.   +4 more
europepmc   +1 more source

Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria. [PDF]

Drug Des Devel Ther
Chen C, Zhong J, Xiong D.
europepmc   +1 more source

Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder. [PDF]

Case Rep Neurol Med
Tsuzaki K, Mitsui G, Inagaki Y, Uehara N, Wada S, Hamano T.   +5 more
europepmc   +1 more source

Complement diagnostics and therapeutics for the pediatric population: early successes and opportunities for further advancement. [PDF]

Front Pharmacol
Whelan RS, Dixon BP.
europepmc   +1 more source

Time-Related Burden of Treatment With Parenterally Administered Complement Inhibitors: A Mixed Methods Observational Study Exploring Experiences among Patients With Paroxysmal Nocturnal Hemoglobinuria. [PDF]

Health Sci Rep
Dingli D, Broderick L, Rizio AA, Rucker S, LaGasse K, Carty MK, Burton E, Gordon S, Yen GP, Paulose J, Geevarghese A, Lee S.   +11 more
europepmc   +1 more source

Breakthrough serogroup Y meningococcal disease in a vaccinated patient with myasthenia gravis receiving ravulizumab: a case report. [PDF]

BMC Infect Dis
Strugar SŠ, Petrović P, Butić I, Gjurašin B, Kutleša M.   +4 more
europepmc   +1 more source

Meningococcemia in a Boy with Dense Deposit Disease Receiving the C5 Complement Inhibitor Ravulizumab: A Case Report. [PDF]

Clin Pract Cases Emerg Med
Gonedes AJ, Martinez A, Greissman AM, Atia H, Boccio E.   +4 more
europepmc   +1 more source